In lung cancer, CAR-T cells with dual targets on HER2 and HLA-A02 enhance tumor specificity and address on-target off-tumor toxicity in HER2+ lung cancer cell lines with HLA-A02 loss of heterozygosity (53). This evidence concerns the gene ERBB2 and neoplasm.